Avidity Biosciences (RNA) Revenue & Revenue Breakdown
Avidity Biosciences Revenue Highlights
Latest Revenue (Y)
$9.56M
Latest Revenue (Q)
$2.04M
Avidity Biosciences Revenue by Period
Avidity Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $9.56M | 3.64% |
| 2022-12-31 | $9.22M | -1.09% |
| 2021-12-31 | $9.33M | 37.41% |
| 2020-12-31 | $6.79M | 192.67% |
| 2019-12-31 | $2.32M | 511.87% |
| 2018-12-31 | $379.00K | - |
Avidity Biosciences generated $9.56M in revenue during NA 2023, up 3.64% compared to the previous quarter, and up 2522.43% compared to the same period a year ago.
Avidity Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.04M | -42.28% |
| 2024-03-31 | $3.54M | 61.56% |
| 2023-12-31 | $2.19M | -22.18% |
| 2023-09-30 | $2.82M | 21.68% |
| 2023-06-30 | $2.32M | 3.72% |
| 2023-03-31 | $2.23M | -19.36% |
| 2022-12-31 | $2.77M | 11.56% |
| 2022-09-30 | $2.48M | 13.96% |
| 2022-06-30 | $2.18M | 21.34% |
| 2022-03-31 | $1.79M | -3.08% |
| 2021-12-31 | $1.85M | -14.38% |
| 2021-09-30 | $2.16M | -17.03% |
| 2021-06-30 | $2.61M | -3.59% |
| 2021-03-31 | $2.70M | 26.24% |
| 2020-12-31 | $2.14M | 22.68% |
| 2020-09-30 | $1.75M | 13.30% |
| 2020-06-30 | $1.54M | 13.48% |
| 2020-03-31 | $1.36M | -6.02% |
| 2019-12-31 | $1.45M | 122.31% |
| 2019-09-30 | $650.00K | 190.18% |
| 2019-06-30 | $224.00K | 100.00% |
| 2019-03-31 | - | - |
Avidity Biosciences generated $2.04M in revenue during Q2 2024, up -42.28% compared to the previous quarter, and up 91.58% compared to the same period a year ago.
Avidity Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $78.50M | $76.50M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| RLAY | Relay Therapeutics | $25.55M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| SWTX | SpringWorks Therapeutics | $5.45M | $21.01M |
| IGMS | IGM Biosciences | $2.13M | $497.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| CERE | Cerevel Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| AKRO | Akero Therapeutics | - | - |
RNA Revenue FAQ
What is Avidity Biosciences’s yearly revenue?
Avidity Biosciences's yearly revenue for 2023 was $9.56M, representing an increase of 3.64% compared to 2022. The company's yearly revenue for 2022 was $9.22M, representing a decrease of -1.09% compared to 2021. RNA's yearly revenue for 2021 was $9.33M, representing an increase of 37.41% compared to 2020.
What is Avidity Biosciences’s quarterly revenue?
Avidity Biosciences's quarterly revenue for Q2 2024 was $2.04M, a -42.28% decrease from the previous quarter (Q1 2024), and a -11.70% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $3.54M, a 61.56% increase from the previous quarter (Q4 2023), and a 58.67% increase year-over-year (Q1 2023). RNA's quarterly revenue for Q4 2023 was $2.19M, a -22.18% decrease from the previous quarter (Q3 2023), and a -20.80% decrease year-over-year (Q4 2022).
What is Avidity Biosciences’s revenue growth rate?
Avidity Biosciences's revenue growth rate for the last 3 years (2021-2023) was 2.51%, and for the last 5 years (2019-2023) was 312.25%.